- Report
- March 2025
- 175 Pages
Global
From €4262EUR$4,490USD£3,595GBP
- Report
- February 2025
- 200 Pages
Global
From €4262EUR$4,490USD£3,595GBP
- Report
- February 2025
- 200 Pages
Global
From €4262EUR$4,490USD£3,595GBP
- Report
- February 2025
- 200 Pages
Global
From €4262EUR$4,490USD£3,595GBP
- Report
- December 2024
- 150 Pages
Global
From €4604EUR$4,850USD£3,884GBP
- Report
- August 2024
- 150 Pages
Global
From €4604EUR$4,850USD£3,884GBP
- Report
- August 2024
- 150 Pages
Global
From €4604EUR$4,850USD£3,884GBP
- Report
- August 2024
- 150 Pages
Global
From €4604EUR$4,850USD£3,884GBP
- Report
- August 2024
- 137 Pages
Global
From €2847EUR$2,999USD£2,402GBP
- Report
- August 2024
- 200 Pages
Global
From €3673EUR$3,869USD£3,098GBP
- Report
- January 2025
- 185 Pages
Global
From €4272EUR$4,500USD£3,603GBP
- Report
- July 2024
- 185 Pages
Global
From €4272EUR$4,500USD£3,603GBP
- Report
- January 2025
- 194 Pages
Global
From €2373EUR$2,500USD£2,002GBP
- Report
- August 2024
- 170 Pages
Global
From €2373EUR$2,500USD£2,002GBP
- Report
- February 2025
- 180 Pages
Global
From €4272EUR$4,500USD£3,603GBP
- Report
- January 2025
- 180 Pages
Global
From €4272EUR$4,500USD£3,603GBP
- Report
- March 2024
- 120 Pages
Middle East, Africa
From €1424EUR$1,500USD£1,201GBP
- Report
- May 2022
- 231 Pages
Global
From €4556EUR$4,799USD£3,843GBP
- Report
- May 2022
- 365 Pages
Global
From €4556EUR$4,799USD£3,843GBP
- Report
- June 2023
- 364 Pages
Global
From €4847EUR$5,284USD£3,950GBP

The Vaccine Adjuvant market is a subset of the Vaccines market, which is composed of products that are used to enhance the effectiveness of vaccines. Vaccine adjuvants are substances that are added to vaccines to increase the body's immune response to the vaccine. Adjuvants can be either natural or synthetic, and can be used to increase the potency of a vaccine, reduce the amount of antigen needed, or to extend the duration of the vaccine's effectiveness. Vaccine adjuvants are used in a variety of vaccines, including those for influenza, hepatitis, and human papillomavirus.
Some companies in the Vaccine Adjuvant market include GlaxoSmithKline, Merck, Sanofi, and Novartis. Show Less Read more